Entrada Therapeutics Inc (TRDA)

Mar 24, 2025, 7:00 AM EDT - 10 days ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Feb 27, 2025, 7:00 AM EST - 5 weeks ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 7:00 AM EST - 5 weeks ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 19, 2025, 11:31 AM EST - 6 weeks ago

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 3, 2025, 7:00 AM EST - 2 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Jan 30, 2025, 4:05 PM EST - 2 months ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Dec 18, 2024, 7:00 AM EST - 3 months ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Oct 9, 2024, 7:00 AM EDT - 6 months ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Sep 24, 2024, 7:00 AM EDT - 6 months ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 17, 2024, 8:30 AM EDT - 7 months ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 6, 2024, 7:00 AM EDT - 7 months ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Jun 24, 2024, 7:15 AM EDT - 10 months ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 6:00 AM EDT - 10 months ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 3, 2024, 7:00 AM EDT - 10 months ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 11 months ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 7, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

Nov 22, 2023, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Sep 21, 2023, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 8, 2023, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 3, 2023, 6:39 PM EDT - 1 year ago

Entrada Therapeutics: Early Stage But Interesting

Jun 6, 2023, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Apr 4, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Mar 29, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 6, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Dec 19, 2022, 4:30 PM EST - 2 years ago

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Dec 8, 2022, 8:24 AM EST - 2 years ago

Entrada Therapeutics shares jump on collaboration with Vertex

Dec 8, 2022, 7:00 AM EST - 2 years ago

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

VRTX

Nov 7, 2022, 7:00 AM EST - 2 years ago

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Aug 30, 2022, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

Jul 19, 2022, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

Jul 6, 2022, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

Jun 1, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

May 12, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2022 Financial Results

May 11, 2022, 9:30 AM EDT - 3 years ago

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

Apr 18, 2022, 9:48 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch: Aterian And Newegg Remain In Top Two Positions, Cannabis Company Joins List Week Of 4/20

ATER NEGG BEEM

Mar 15, 2022, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Feb 23, 2022, 8:00 AM EST - 3 years ago

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

Jan 5, 2022, 8:00 AM EST - 3 years ago

Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel

Dec 17, 2021, 8:00 AM EST - 3 years ago

Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes

Dec 9, 2021, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Third Quarter 2021 Financial Results

Nov 2, 2021, 4:26 PM EDT - 3 years ago

Entrada Therapeutics Announces Closing of Initial Public Offering